Ontario-based, Nicoya Lifesciences, is in the process of completing a prototype of a low-cost, single-use device that tests for active SARS-CoV-2 infection, variants and, eventually, other viruses. The novel test is called Atlas.
Users administer the Atlas test themselves with a simple saliva collection kit. After that, a smartphone application provides results, in only 20 minutes – without complex lab equipment or highly trained technicians.
Atlas was developed with funding from the National Research Council of Canada (NRC) as part of a joint challenge issued with the Public Health Agency of Canada (PHAC) through the government’s Innovative Solutions Canada (ISC) program.
Universal PropTech Confirms Launch of ISBRG Corp s SpotLight-19(C) Clinical Trial and New R&D Funding Assistance streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
From: Atlantic Canada Opportunities Agency
Audioptics Medical receives federal support to further test and develop its inner ear imaging technology
May 11, 2021 · Halifax, Nova Scotia · Atlantic Canada Opportunities Agency (ACOA)
Research and development play important roles in continuing to create non-invasive healthcare solutions for Canadians and people around the world. That’s why Audioptics Medical is working to test, develop and prototype the Ossiview Middle Ear Imaging system to help clinicians provide safe and accurate diagnoses to people experiencing inner ear conditions.
Federal support for innovative healthcare
Today, Andy Fillmore, Parliamentary Secretary to the Minister of Infrastructure and Communities and Member of Parliament for Halifax, announced contributions totalling up to $732,052 to Audioptics to help further develop its imaging technology and establish manufacturing capabilities. The announcement was made on behalf of the Honourable Mélanie Joly, Mini
from Canadian Broadcasting Corporation
Sunday, May 2, 2021
COVID-19 vaccine maker Providence says it s leaving Canada after calls for more federal support go unanswered
A volunteer receives an injection in this undated handout image provided by Providence Therapeutics. (Providence Therapeutics/The Canadian Press) The head of a homegrown company behind a promising COVID-19 vaccine says he s ready to pull his company out of Canada and take its product elsewhere after calls for more substantial federal support went unanswered. Brad Sorenson, the CEO of Calgary-based Providence Therapeutics, told CBC News he s had enough of the runaround from federal and provincial governments and he s working with the company s board of directors to move its operations overseas to focus on developing a vaccine for people in the southern hemisphere.